OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Synovial inflammation in osteoarthritis progression	406
Mechanisms and therapeutic implications of cellular senescence in osteoarthritis	371
Global epidemiology of systemic lupus erythematosus	344
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	280
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	252
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	216
Systemic and organ-specific immune-related manifestations of COVID-19	211
The gut–joint axis in rheumatoid arthritis	210
Early-stage symptomatic osteoarthritis of the knee — time for action	189
A new immunometabolic perspective of intervertebral disc degeneration	183
Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis	178
Toll-like receptor signalling in B cells during systemic lupus erythematosus	174
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?	162
Global epidemiology of vasculitis	158
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis	157
Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison	157
Cell-based strategies for IVD repair: clinical progress and translational obstacles	148
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis	148
The non-coding RNA interactome in joint health and disease	134
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	125
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	118
Rheumatic disease and COVID-19: epidemiology and outcomes	117
Oral surveillance and JAK inhibitor safety: the theory of relativity	115
The endothelium–bone axis in development, homeostasis and bone and joint disease	113
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases	104

Global epidemiology of rheumatoid arthritis	103
The decisive early phase of bone regeneration	99
TNF in the era of immune checkpoint inhibitors: friend or foe?	94
Current and future therapies for primary Sjögren syndrome	91
The evolution of nerve growth factor inhibition in clinical medicine	90
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	85
Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission	84
Location, location, location: how the tissue microenvironment affects inflammation in RA	84
Immune cartography of macrophage activation syndrome in the COVID-19 era	83
Axial spondyloarthritis: concept, construct, classification and implications for therapy	79
Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies	77
Interleukin-2 and regulatory T cells in rheumatic diseases	73
State-of-the-art evidence in the treatment of systemic sclerosis	73
Targeting interferon-γ in hyperinflammation: opportunities and challenges	73
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation	72
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research	69
Treatment of axial spondyloarthritis: an update	69
Lyme arthritis: linking infection, inflammation and autoimmunity	68
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	66
Psoriatic arthritis from a mechanistic perspective	65
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases	65
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care	65
Cardiovascular effects of approved drugs for rheumatoid arthritis	64
Why remission is not enough: underlying disease mechanisms in RA that prevent cure	63
Biological classification of childhood arthritis: roadmap to a molecular nomenclature	63
Insights into the biology and therapeutic implications of TNF and regulatory T cells	63
Vascular Behçet syndrome: from pathogenesis to treatment	63
Disorders of ubiquitylation: unchained inflammation	63
Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential	62
Inflammation and DNA damage: cause, effect or both	56
Matrix metalloproteinases in arthritis: towards precision medicine	55